X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs MERCK LTD - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA MERCK LTD GSK PHARMA/
MERCK LTD
 
P/E (TTM) x 55.3 38.1 145.3% View Chart
P/BV x 9.9 5.0 197.9% View Chart
Dividend Yield % 1.3 0.6 226.2%  

Financials

 GSK PHARMA   MERCK LTD
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
MERCK LTD
Dec-16
GSK PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs3,8381,060 362.1%   
Low Rs2,637623 423.3%   
Sales per share (Unadj.) Rs354.2632.4 56.0%  
Earnings per share (Unadj.) Rs39.845.7 87.0%  
Cash flow per share (Unadj.) Rs42.962.3 68.8%  
Dividends per share (Unadj.) Rs30.0011.00 272.7%  
Dividend yield (eoy) %0.91.3 70.9%  
Book value per share (Unadj.) Rs236.9388.8 60.9%  
Shares outstanding (eoy) m84.7016.60 510.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.11.3 687.0%   
Avg P/E ratio x81.418.4 442.3%  
P/CF ratio (eoy) x75.513.5 559.2%  
Price / Book Value ratio x13.72.2 631.4%  
Dividend payout %75.424.1 313.6%   
Avg Mkt Cap Rs m274,21613,969 1,963.0%   
No. of employees `0004.71.6 296.7%   
Total wages/salary Rs m4,8301,487 324.9%   
Avg. sales/employee Rs Th6,387.06,631.9 96.3%   
Avg. wages/employee Rs Th1,028.3939.2 109.5%   
Avg. net profit/employee Rs Th717.1479.4 149.6%   
INCOME DATA
Net Sales Rs m30,00010,498 285.8%  
Other income Rs m728242 300.4%   
Total revenues Rs m30,72810,741 286.1%   
Gross profit Rs m4,1901,135 369.0%  
Depreciation Rs m263276 95.5%   
Interest Rs m00-   
Profit before tax Rs m4,6551,102 422.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,744343 508.0%   
Profit after tax Rs m3,368759 443.8%  
Gross profit margin %14.010.8 129.1%  
Effective tax rate %37.531.1 120.3%   
Net profit margin %11.27.2 155.3%  
BALANCE SHEET DATA
Current assets Rs m16,7426,410 261.2%   
Current liabilities Rs m7,2028,828 81.6%   
Net working cap to sales %31.8-23.0 -138.0%  
Current ratio x2.30.7 320.2%  
Inventory Days Days5258 89.8%  
Debtors Days Days2138 54.1%  
Net fixed assets Rs m8,6351,406 614.0%   
Share capital Rs m847166 510.2%   
"Free" reserves Rs m19,2226,286 305.8%   
Net worth Rs m20,0696,455 310.9%   
Long term debt Rs m100-   
Total assets Rs m30,0388,828 340.3%  
Interest coverage xNMNM-  
Debt to equity ratio x00-  
Sales to assets ratio x1.01.2 84.0%   
Return on assets %11.28.6 130.4%  
Return on equity %16.811.8 142.7%  
Return on capital %25.517.1 149.1%  
Exports to sales %08.3 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA869 0.0%   
Imports (cif) Rs mNA2,209 0.0%   
Fx inflow Rs m528959 55.1%   
Fx outflow Rs m7,1932,612 275.4%   
Net fx Rs m-6,665-1,653 403.2%   
CASH FLOW
From Operations Rs m2,3601,070 220.5%  
From Investments Rs m3,008-750 -401.2%  
From Financial Activity Rs m-5,108-150 3,409.6%  
Net Cashflow Rs m260171 152.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 51.8 97.9%  
Indian inst/Mut Fund % 10.2 18.2 56.0%  
FIIs % 23.8 1.0 2,380.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 29.1 52.9%  
Shareholders   102,036 28,591 356.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   PFIZER  ABBOTT INDIA  PLETHICO PHARMA  WYETH LTD  TORRENT PHARMA  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum; Energy and IT Stocks Witness Buying(12:30 pm)

Stock markets in India are presently trading on a positive note. Sectoral indices are trading on a positive note with stocks in the energy sector and IT sector witnessing maximum buying interest.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Beware the 5th year of the Modi Regime(The Honest Truth)

May 22, 2018

2017 was a great year for the market. You were rewarded for taking excessive risk. But Ajit Dayal believes 2018 will be different. You will be rewarded for doing the opposite. Read on to know more...

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


May 25, 2018 02:03 PM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - ALKEM LABORATORIES COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS